MIRA
INFORM REPORT
|
Report Date : |
26.06.2007 |
IDENTIFICATION DETAILS
|
Name : |
PHARMA SWEDE |
|
|
|
|
Registered Office : |
El
Obour Buildings, 6th Floor, Office No. 67, 11, Salah Salem Road, Nasr City, Cairo |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.12.2006 |
|
|
|
|
Date of Incorporation : |
1995 |
|
|
|
|
Legal Form : |
Egyptian Joint Stock Company |
|
|
|
|
Line of Business : |
Engaged
in the manufacture and distribution of pharmaceutical veterinary preparations,
antibiotics and vitamins. |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
US$ 200,000 |
|
|
|
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Usually correct |
|
|
|
|
Litigation : |
Clear |
SUMMARY
Company Name :
PHARMA
SWEDE
Country of Origin :
Legal Form : Egyptian Joint Stock Company
Registration Date : 1995
Authorised Capital : £E 50,000,000
Issued Capital : £E 12,000,000
Paid up Capital : £E 12,000,000
Total Workforce : 35
Line of Business :
Manufacture and distribution of pharmaceutical
veterinary preparations, antibiotics and vitamins.
Financial Condition : Fair
Payments : Nothing detrimental uncovered
Operating Trend : Steady
COMPANY NAME
PHARMA SWEDE
ADDRESS
Registered & Physical Address
Building : El Obour
Buildings, 6th Floor, Office No.67
Street : 11,
Area :
Town :
Country :
Telephone : (20-2) 4022319
/ 4022312
Facsimile : (20-2) 4016982
Premises
Subject operates from
a medium sized suite of offices that are rented and located in the Central
Business Area of Cairo.
Branch Office (s)
Location Description
·
Industrial Zone B3 Owned
factory premises
Sharkeya
Tenth of
Tel:
(20-15) 370016 / 370017 / 370018
Fax: (20-15) 363971
KEY PRINCIPALS
·
Dr. Asaad Badran Chairman
·
Walid Mohamed Vice
Chairman
·
Dr. Lefah Eissa Managing
Director
·
Maher Attia Finance
Manager
·
Youssef Gabr Production
Manager
·
Dr. Ibrahim El Gabry Sales
Manager
LEGAL FORM &
OWNERS
Date of Establishment : 1995
Legal Form :
Societe Anonyme Egyptienne
– SAE (Egyptian Joint Stock Company)
Authorised
Capital : £E 50,000,000
Issued Capital : £E 12,000,000
Paid up Capital : £E 12,000,000
Name of Shareholder
(s) Percentage
·
Pharma Swede Lund 95%
·
Dr. Asaad Badran 5%
Note to the Legal Form
The Egyptian Company Law provides that the capital of a Societe
Anonyme Egyptienne - SAE – should not be less than £E 500,000 if shares are
offered to the public and £E 250,000 if not. If shares are offered to the
public they are freely transferable, if not, transfer may be restricted.
Liability of shareholders is limited.
LINE OF BUSINESS
Operations : Engaged in the
manufacture and distribution of pharmaceutical veterinary preparations,
antibiotics and vitamins.
Import Countries
:
Brand Names : PHARMA SWEDE
& AVICO
Operating Trend
: Steady
Subject has a
workforce of 35 employees.
FINANCIAL HIGHLIGHTS
Financial
highlights provided by outside sources are given below :
Currency : Egyptian
Pounds (£E)
Year
Ending 31/12/05: Year
Ending 31/12/06:
Total Revenue £E 18,600,000 £E 20,100,000
Local sources
consider subject’s financial condition to be Fair.
BANKERS
·
Arab
Bank Plc
28,
PO Box: 2006
Tel: (20-2) 5746218
PAYMENT HISTORY
No complaints
regarding subject’s payments have been reported.
GENERAL COMMENTS
Opinion on the
credit figure of US$ 100,000:
During the course
of this investigation nothing detrimental was uncovered regarding subject’s
operating history or the manner in which payments are fulfilled. As such the
company is considered to be a fair trade risk and the above credit figure is
within subject’s financial means.
Maximum suggested
credit figure: US$ 200,000
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit consideration.
Capability to overcome financial difficulties seems comparatively below
average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)